<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Summary of data in clinical trials relating to the use of saffron and ginkgo EGb761</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" rowspan="1" colspan="1">Subjects (
     <italic>n</italic> = eyes)
    </th>
    <th align="left" rowspan="1" colspan="1">Treatment</th>
    <th align="left" rowspan="1" colspan="1">Type of study</th>
    <th align="left" rowspan="1" colspan="1">Visual parameters and results</th>
    <th align="left" rowspan="1" colspan="1">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Early AMD (
     <italic>n</italic> = 25)
    </td>
    <td align="left" rowspan="1" colspan="1">20 mg/d</td>
    <td align="left" rowspan="1" colspan="1">Double-blind, placebo controlled, crossover, RCT 3-month period with cross over for another 3 months</td>
    <td align="left" rowspan="1" colspan="1">fERG: ↑ in amplitude in patients, but not in placebo group</td>
    <td align="left" rowspan="1" colspan="1">Falsini et al., 2010</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Early AMD (
     <italic>n</italic> = 29)
    </td>
    <td align="left" rowspan="1" colspan="1">20 mg/d</td>
    <td align="left" rowspan="1" colspan="1">Longitudinal interventional open-label study 3 monthly follow-ups over a 15-month period of treatment</td>
    <td align="left" rowspan="1" colspan="1">Mean VA: ↑ 2 lines fERG: ↑ 0.3 log units</td>
    <td align="left" rowspan="1" colspan="1">Piccardi et al., 2012</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Early AMD (
     <italic>n</italic> = 33) Presence of known AMD risk genotypes
    </td>
    <td align="left" rowspan="1" colspan="1">20 mg/d</td>
    <td align="left" rowspan="1" colspan="1">Longitudinal 3 monthly follow-ups over a 12-month period</td>
    <td align="left" rowspan="1" colspan="1">fERG: ↑ amplitude and sensitivity amplitude that stabilized after 3 months independent of genotype</td>
    <td align="left" rowspan="1" colspan="1">Marangoni et al., 2013</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Dry and wet AMD (
     <italic>n</italic> = 40)
    </td>
    <td align="left" rowspan="1" colspan="1">15 mg, twice a day</td>
    <td align="left" rowspan="1" colspan="1">Placebo-controlled, RCT 6-month period with follow-ups at 3 and 6 months</td>
    <td align="left" rowspan="1" colspan="1">CMT: ↓ in saffron and placebo groups in wet AMD, but not in dry AMD ERG: ↑ amplitude in the saffron group (dry and wet AMD) compared to placebo after 3 months, but not 6 months</td>
    <td align="left" rowspan="1" colspan="1">Lashay et al., 2016</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Mild/moderate dry AMD (
     <italic>n</italic> = 54)
    </td>
    <td align="left" rowspan="1" colspan="1">50 mg/d</td>
    <td align="left" rowspan="1" colspan="1">Placebo-controlled, RCT three months</td>
    <td align="left" rowspan="1" colspan="1">CMT: unchanged BCVA: ↑ in saffron, but not in placebo group CS: ↑ in saffron, but not in placebo group</td>
    <td align="left" rowspan="1" colspan="1">Riazi et al., 2017</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Mild/moderate AMD (
     <italic>n</italic> = 96) 73.2% consuming AREDS supplements
    </td>
    <td align="left" rowspan="1" colspan="1">20 mg/d</td>
    <td align="left" rowspan="1" colspan="1">Double-blind, placebo-controlled, crossover, RCT 3 months followed by crossover for 3 months</td>
    <td align="left" rowspan="1" colspan="1">BCVA: ↑ in saffron group and AREDS + saffron, but not in placebo mfERG response density: ↑ in AREDS+saffron, but not in the saffron or placebo group mfERG latency: ↓ in saffron group, but not in placebo group</td>
    <td align="left" rowspan="1" colspan="1">Broadhead et al., 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Intermediate AMD (
     <italic>n</italic> = 42) Two groups (
     <italic>n</italic> = 19) lutein/zeaxanthin 
     <italic>n</italic> = 23 saffron
    </td>
    <td align="left" rowspan="1" colspan="1">–</td>
    <td align="left" rowspan="1" colspan="1">Longitudinal open-label study 8 monthly follow-ups over a 29 (±5)-month period</td>
    <td align="left" rowspan="1" colspan="1">fERG Saffron treated AMD patients: Visual function remains stable Lutein/zeaxanthin treated patients: Deterioration of retinal functions</td>
    <td align="left" rowspan="1" colspan="1">Di Marco et al., 2019</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>AREDS: Age-related eye disease study; BCVA: best-corrected visual acuity; CMT: central macular thickness; CS: contrast sensitivity; ERG: electroretinography; fERG: focal electroretinography; mfERG: multifocal electroretinography; RCT: randomized clinical trial.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
